Loading...
Under maintenance — back shortly
Cholesterol lowering→amyloid-β reduction→neuroprotection
Atorvastatin may reduce amyloid-β production and neuroinflammation by modulating cholesterol metabolism in the brain and inhibiting NF-κB-driven neurodegeneration; 3 papers with 30% support ratio and animal model evidence suggest plausibility, though clinical trials have shown mixed results. This is a legitimate novel repurposing candidate distinct from dementia broadly.
“Atorvastatin (ATOR) was administered orally and was used to treat AD in adult male Wistar rats aged between 200 and 250 g. We confirmed that ATOR administration significantly attenuates the Aβ-induced cognitive decline targeted mitochondrial-mediated age-dependent disease progression.”
— HMGCR Inhibitor Restores Mitochondrial Dynamics by Regulating Signaling Cascades in a Rodent Alzheimer's Disease Model. (2024)DOI“Atorvastatin's Reduction of Alzheimer's Disease and Possible Alteration of Cognitive Function in Midlife as well as its Treatment.”
— Atorvastatin's Reduction of Alzheimer's Disease and Possible Alteration of Cognitive Function in Midlife as well as its Treatment. (2022)DOI“Atorvastatin with magnesium L-threonate provides a better beneficial protective effect against AD than atorvastatin alone.”
— Enhanced Neuroprotective Synergy of Atorvastatin and Magnesium L-Threonate in a Rat Model of Alzheimer's Disease Induced by Aluminum Chloride. (2023)DOI“Atorvastatin treatment has improved memory and cognition in some patients with diabetes mellitus and Alzheimer disease.”
— Atorvastatin reduces alloxan-induced impairment of aversive stimulus memory in mice. (2022)DOI